
Quarterly report 2025-Q4
added 02-11-2026
Organovo Holdings Cash Flow 2011-2026 | ONVO
Annual Cash Flow Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-9.46 M | -14.7 M | -12.4 M | -13.3 M | -14.9 M | -20.4 M | -28.9 M | - | - | - | -15.6 M | - | -9.69 M | -1.91 M |
Depreciation & Amortization |
266 K | 280 K | 293 K | 41 K | 1.14 M | 980 K | 1.27 M | 1.15 M | 815 K | 472 K | 387 K | - | 195 K | 68 K |
Accounts Payables |
1.64 M | 627 K | 331 K | 281 K | 720 K | 628 K | 464 K | 1.17 M | 787 K | 1.39 M | 326 K | 641 K | 425 K | 658 K |
Accounts Receivables |
30 K | 33 K | 152 K | - | 111 K | 503 K | 883 K | 647 K | 259 K | - | - | - | - | - |
Total Inventories |
- | 297 K | - | - | - | 490 K | 842 K | 550 K | 334 K | 66 K | 63 K | 88 K | 360 K | 292 K |
All numbers in USD currency
Quarterly Cash Flow Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | -3.94 M | - | - | - | -2.98 M | - | - | - | -5.31 M | - | - | -7.68 M | -2.41 M | - | - | -6.91 M | -3.56 M | - | - | -11.2 M | -9.72 M | -2.57 M | - | -11.7 M | -11.1 M | -5.94 M | - | -15.3 M | -11.3 M | - | - | - | -10.7 M | - | - | - | - | - | - | - | - | - | - | - | 3.4 M | - | - | - | -2.66 M | -2.76 M | - | -6.14 M | -4.16 M | -3.56 M | - | -647 | -10.5 K | -140 K |
Depreciation & Amortization |
- | - | 61 K | - | - | - | 70 K | - | - | - | 67 K | - | - | 234 K | 50 K | - | - | 96 K | 59 K | - | - | 18 K | 8 K | 4 K | - | 1.14 M | 379 K | 205 K | - | 824 K | 570 K | - | - | - | 326 K | - | - | 824 K | 502 K | - | - | 560 K | 324 K | - | - | 334 K | 208 K | - | - | 288 K | 190 K | 80 K | - | 178 K | 100 K | 17 K | - | 49.9 K | 32.4 K | 15.6 K |
Accounts Payables |
671 K | 580 K | 673 K | 1.64 M | 930 K | 419 K | 1.12 M | 627 K | 471 K | 435 K | 488 K | 331 K | 242 K | 441 K | 130 K | 415 K | 605 K | 958 K | 577 K | 281 K | 411 K | 201 K | 110 K | 720 K | 822 K | 152 K | 553 K | 628 K | 647 K | 449 K | 396 K | 464 K | 452 K | 477 K | 558 K | 1.17 M | 722 K | 754 K | 481 K | 787 K | 466 K | 567 K | 1.03 M | 1.39 M | 495 K | 530 K | 839 K | 326 K | 311 K | 477 K | 374 K | 641 K | 425 K | 61.3 K | 260 K | 441 K | 658 K | 658 K | 658 K | 658 K |
Accounts Receivables |
33 K | 32 K | 32 K | 30 K | 26 K | 29 K | 48 K | 33 K | 33 K | 55 K | 149 K | 152 K | 76 K | - | - | - | - | - | - | - | - | 19 K | 84 K | 111 K | 165 K | 619 K | 538 K | 503 K | 547 K | 475 K | 628 K | 883 K | 1.17 M | 1.03 M | 772 K | 647 K | 1.03 M | 606 K | 103 K | 259 K | 165 K | 180 K | 132 K | - | - | 30 K | 60 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
- | - | - | - | - | 640 K | 408 K | 297 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 351 K | 506 K | 490 K | 1.05 M | 1.04 M | 1.04 M | 842 K | 605 K | 496 K | 461 K | 550 K | 328 K | 445 K | 512 K | 334 K | 71 K | 68 K | 69 K | 66 K | 69 K | 70 K | 71 K | 63 K | 82 K | 74 K | 85 K | 88 K | 360 K | 312 K | 527 K | 337 K | 292 K | 292 K | 292 K | 292 K |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Organovo Holdings, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Agilent Technologies
A
|
$ 115.35 | -2.33 % | $ 35.1 B | ||
|
Anixa Biosciences
ANIX
|
$ 2.81 | -2.7 % | $ 91.2 K | ||
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Brainsway Ltd.
BWAY
|
$ 12.28 | -2.69 % | $ 99.4 M | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 22.48 | -1.58 % | $ 234 M | ||
|
Bioventus
BVS
|
$ 8.45 | -7.14 % | $ 563 M | ||
|
Celcuity
CELC
|
$ 114.85 | -0.34 % | $ 4.53 B | ||
|
Castle Biosciences
CSTL
|
$ 27.23 | -2.44 % | $ 756 M | ||
|
Charles River Laboratories International
CRL
|
$ 175.23 | -3.37 % | $ 8.69 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Co-Diagnostics
CODX
|
- | - | $ 79.8 M | ||
|
Fulgent Genetics
FLGT
|
$ 14.59 | 2.41 % | $ 441 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
Biodesix
BDSX
|
$ 18.61 | 17.37 % | $ 2.41 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
$ 124.76 | -2.71 % | $ 19.8 B | ||
|
IQVIA Holdings
IQV
|
$ 175.33 | -1.8 % | $ 30.1 B | ||
|
BioNano Genomics
BNGO
|
$ 1.11 | -1.36 % | $ 1.41 M | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 199.8 | -2.07 % | $ 22.2 B | ||
|
Danaher Corporation
DHR
|
$ 195.75 | -2.99 % | $ 140 B | ||
|
IDEXX Laboratories
IDXX
|
$ 607.19 | -1.9 % | $ 48.8 B | ||
|
Exact Sciences Corporation
EXAS
|
$ 103.5 | 0.17 % | $ 19.5 B | ||
|
DarioHealth Corp.
DRIO
|
$ 9.69 | -3.0 % | $ 275 M | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 269.52 | -2.34 % | $ 22.4 B | ||
|
DexCom
DXCM
|
$ 68.5 | -3.1 % | $ 26.7 B | ||
|
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | ||
|
ICON Public Limited Company
ICLR
|
$ 107.08 | -3.19 % | $ 8.83 B | ||
|
Lantheus Holdings
LNTH
|
$ 72.86 | -4.53 % | $ 4.92 B | ||
|
CareDx, Inc
CDNA
|
$ 17.91 | -4.48 % | $ 954 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Mettler-Toledo International
MTD
|
$ 1 215.85 | -3.66 % | $ 25.1 B | ||
|
Myriad Genetics
MYGN
|
$ 5.15 | 0.29 % | $ 477 M | ||
|
NeoGenomics
NEO
|
$ 8.92 | -2.3 % | $ 1.14 B | ||
|
National Research Corporation
NRC
|
$ 14.48 | 3.13 % | $ 324 M | ||
|
Guardant Health
GH
|
$ 91.56 | -1.1 % | $ 11.5 B | ||
|
Natera
NTRA
|
$ 196.94 | -0.1 % | $ 19.4 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
OPKO Health
OPK
|
$ 1.18 | 0.43 % | $ 819 M | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |